Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC33 vs placebo in second-line unresectable hepatocellular carcinoma
2011-003574-84Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing GC33 arm with Placebo arm (2 arms). Primary endpoint: Progression-free survival. Started Nov 2011; status: completed.
02
Drugs
codrituzumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-003574-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003574-84.